永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

未开盘 03-16 16:08:20

2.610

+0.060

+2.35%

最高2.610	最低2.480	成交量6.30万
今开2.550	昨收2.550	日振幅5.10%
总市值16.13亿	流通市值16.13亿	总股本6.18亿
成交额15.74万	换手率0.01%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.61,"timestamp":1773648500676,"preClose":2.55,"halted":0,"volume":63000,"delay":0,"changeRate":0.023529411764705906,"floatShares":618000000,"shares":618000000,"eps":-0.363229,"marketStatus":"未开盘","change":0.06,"latestTime":"03-16 16:08:20","open":2.55,"high":2.61,"low":2.48,"amount":157410,"amplitude":0.05098,"askPrice":2.62,"askSize":10000,"bidPrice":2.47,"bidSize":20000,"shortable":0,"etf":0,"ttmEps":-0.397,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773711000000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.55,"openAndCloseTimeList":[[1773624600000,1773633600000],[1773637200000,1773648000000]],"volumeRatio":0.1829465901135477,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2619245504","title":"信立泰（002294）披露变更部分募集资金用途用于高血压创新药临床研究公告，3月16日股价上涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619245504?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:12","pubTimestamp":1773652338,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，信立泰报收于55.35元，较前一交易日上涨5.65%，最新总市值为617.05亿元。近日，深圳信立泰药业股份有限公司发布《关于签订募集资金三方监管协议的公告》。公告显示，公司因变更部分募集资金用途，将原项目“S086沙库巴曲阿利沙坦钙中国II/III期临床研究及上市注册项目”中的30,100万元募集资金用于新项目“部分高血压创新药II/III期临床研究及上市注册项目”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600023232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","BK1574","BK0188","BK0183","002294","BK0028","BK0239","06978","159992","BK1161"],"gpt_icon":0},{"id":"2619245814","title":"红日药业：公司并未放弃创新药战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619245814?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:06","pubTimestamp":1773648373,"startTime":"0","endTime":"0","summary":"证券之星消息，红日药业03月16日在投资者关系平台上答复投资者关心的问题。公司被调出深证成指，你却在回复中刻意回避创新药这一核心短板，是否意味着管理层已放弃创新药战略？公司并未放弃创新药战略，创新药仍为公司的核心发展板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600019870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","06978","300026","BK1161","BK1574","BK0188","159992","BK0239"],"gpt_icon":0},{"id":"2619437120","title":"中国创新药进入“深水区”，供应链如何从“赋能”到“共谋”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2619437120","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619437120?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:15","pubTimestamp":1773645306,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛当中国创新药管线占据全球30%的份额，当中国不再是仅仅承接海外授权，而是成为全球大型药企引进资产的重要策源地，整个产业生态的供需关系正在发生微妙的位移。在刚刚落幕的第十一届易贸生物产业大会（BioChina2026）上，这一变化表现得尤为明显。过去，跨国巨头们在中国的叙事往往是“将全球创新带入中国”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603163673062031.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673062031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2619106099","title":"港股通创新药再陷调整，跌到位了吗？机构：当前可加大创新药重视程度和配置仓位","url":"https://stock-news.laohu8.com/highlight/detail?id=2619106099","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619106099?lang=zh_cn&edition=full","pubTime":"2026-03-15 20:00","pubTimestamp":1773576000,"startTime":"0","endTime":"0","summary":"港股医药重回震荡，今日延续弱势，创新药、医疗均不振，100%创新药研发标的——港股通创新药ETF、港股医疗T+0利器——港股通医疗ETF华宝双双续跌1%三连阴，不过场内延续溢价交易，反映买盘依旧活跃。拉长时间看，港股通创新药自去年9月以来震荡调整，至今已有近半年时间，港股通创新药ETF标的指数较去年最高点回撤幅度已超27%。　　方正证券最新观点表示，建议当前可加大创新药重视程度和配置仓位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-15/doc-inhramvn6573396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","VXUS","159992","BK1161","BK1574","BK4588","BK4585"],"gpt_icon":0},{"id":"2619943108","title":"海思科最新公告：获得创新药HSK55879片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619943108","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619943108?lang=zh_cn&edition=full","pubTime":"2026-03-15 16:00","pubTimestamp":1773561644,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称，子公司上海海思盛诺医药科技有限公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意HSK55879片开展两个适应症的临床试验。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500004007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0028","BK1161","BK0033","BK0188","BK0239","BK0077","06978","BK1574","002653"],"gpt_icon":0},{"id":"2619120431","title":"每周股票复盘：热景生物（688068）SGC001创新药Ⅱ期临床首例入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2619120431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619120431?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:16","pubTimestamp":1773512171,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，热景生物报收于124.14元，较上周的134.0元下跌7.36%。本周关注点公司公告汇总：SGC001创新药Ⅱ期临床完成首例受试者入组给药公司公告汇总北京热景生物技术股份有限公司控股子公司北京舜景生物医药技术有限公司自主研发的创新药SGC001注射液Ⅱ期临床研究完成首例受试者入组及给药。SGC001已获中美临床批准，并获FDA快速通道认证，曾获北京市科技计划项目支持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688068","BK1574","BK0239","BK1161","06978","159992"],"gpt_icon":0},{"id":"2619198064","title":"恒瑞医药(600276.SH)：1类创新药海曲泊帕乙醇胺片新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198064","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619198064?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:43","pubTimestamp":1773395002,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到国家药品监督管理局的通知，批准公司自主研发的1类创新药海曲泊帕乙醇胺片新增适应症。批准的适应症：本品联合免疫抑制治疗适用于15岁及以上初治重型再生障碍性贫血(SAA)患者。海曲泊帕乙醇胺片于2021年获批上市两个适应症：1.本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者。2.本品适用于对免疫抑制治疗(IST)疗效不佳的重型再生障碍性贫血(SAA)成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159992","LU0359201612.USD","LU1328615791.USD","LU1781817850.SGD","BK0239","LU2097828474.EUR","LU0405327148.USD","LU1146622755.USD","600276","LU1064130708.USD","LU2495084118.USD","LU2328871848.SGD","LU1655091616.SGD","BK0183","01276","LU2097828557.USD","LU2580892862.HKD","LU1580142542.USD","BK0028","LU2097828714.EUR","LU1064131003.USD","06978","LU1997245094.SGD","LU0359202008.SGD","BK0060","LU0359201885.HKD","LU1255011170.USD","LU2097828631.EUR","LU1997244956.HKD","LU2543165471.USD","BK0188","LU2289578879.USD","BK0196","LU1997245177.USD","LU2580892789.USD","LU0405327494.USD","BK1191","LU1820825898.SGD","LU2148510915.USD","BK1574","LU1969619763.USD","LU1023057109.AUD","BK0012","LU2097828805.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2619610511","title":"创新赛道升温，恒瑞、百济等药企集体加码研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2619610511","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619610511?lang=zh_cn&edition=full","pubTime":"2026-03-13 15:52","pubTimestamp":1773388350,"startTime":"0","endTime":"0","summary":"值得一提的是，在此背景下，恒瑞、百济等大批药企都表示将持续加大研发，聚焦GLP1、肿瘤、ADC、AI 制药等核心赛道。2月26日，百济神州发布2025年度业绩快报公告。据了解，近年来百济神州研发投入呈持续增长态势，2024年单年研发支出达141.4亿元，2025年全年研发费用为约合人民币154.5亿元，同比增长10%。根据季报公布的数字计算，恒瑞医药累计研发投入已超500亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155524a4661da4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155524a4661da4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359202008.SGD","06978","BK1191","LU1023057109.AUD","LU0359201612.USD","BK1161","LU2543165471.USD","LU0359201885.HKD","BK1574"],"gpt_icon":0},{"id":"2619155406","title":"百亿基金经理、24年公募老将离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155406","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619155406?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:59","pubTimestamp":1773327540,"startTime":"0","endTime":"0","summary":"3月12日晚间，广发基金发布公告称，基金经理傅友兴离职，同时卸任旗下管理的全部产品。资深基金经理离职公募行业的基金经理新老交替频频出现，又一位行业早期的老将宣布离职。广发基金发布的公告显示，明星基金经理傅友兴离职，并卸任广发稳健增长和广发睿阳三年定开这两只相关产品的管理。傅友兴此前是行业在职基金经理中，少数拥有超20年公募经验的资深人士，他在基金行业从事投研工作已累计24年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652258191&idx=2&sn=0b3da6b658ec613de0cc9072d47f52db&chksm=85eb285179fc4061302723d78affff7e352ff13483ec3feb251e7fcdaeb264f409be1f01e25c&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2618189126","title":"海思科(002653.SZ)获得创新药HSK44459乳膏两项适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2618189126","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618189126?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:01","pubTimestamp":1773302467,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，涉及药品：“HSK44459乳膏”。HSK44459乳膏是公司自主研发的一个全新的具有独立知识产权的治疗银屑病和特应性皮炎的药物。临床前研究结果表明，本品靶点明确、疗效确切、安全性好，是一款极具开发潜力的小分子药物，临床应用的效益/风险比高，具有广阔的临床应用前景，有望成为银屑病和特应性皮炎的有效治疗药物，解决目前临床用药匮乏的难题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0239","BK1161","BK0188","BK0033","BK0028","IND","159992","BK0077","BK1574","06978"],"gpt_icon":0},{"id":"2618972478","title":"【ETF动向】3月11日银华中证创新药产业ETF基金跌0.74%，份额增加1.06亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2618972478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618972478?lang=zh_cn&edition=full","pubTime":"2026-03-12 08:03","pubTimestamp":1773273819,"startTime":"0","endTime":"0","summary":"证券之星消息，3月11日，银华中证创新药产业ETF基金（159992）跌0.74%，成交额3.75亿元。当日份额增加了1.06亿份，最新份额为182.92亿份，近20个交易日份额减少2.41亿份。当日资金净流出5809.33万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为147.4亿元。银华中证创新药产业ETF基金跟踪标的为中证创新药产业指数，成立（2020-03-20）以来超额回报为-7.28%，近一个月超额回报为-0.03%，管理人为银华基金公司，基金经理为马君 王帅。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200005220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","159992","BK1574"],"gpt_icon":0},{"id":"2618443489","title":"一年狂卖8亿元的流感创新药“失宠”，拿4.8亿元并购却惨遭打脸，南新制药扭亏困局何解？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618443489","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618443489?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:26","pubTimestamp":1773228360,"startTime":"0","endTime":"0","summary":"　　作为曾凭抗流感创新药成名的科创板药企，南新制药（维权）近日披露2025年度业绩快报。截至2025年4月，国内帕拉米韦注射液相关批文为32个，涉及多家知名药企，直接挤压了南新制药的市场空间。　　并购折戟的同时，南新制药的资金压力持续凸显。　　不仅如此，因涉嫌年报信息披露违法违规，南新制药于2025年9月30日收到中国证监会《立案告知书》，目前调查仍在进行中。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-11/doc-inhqrmmk2505340.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-11/doc-inhqrmmk2505340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","688189","06978","159992","BK0239"],"gpt_icon":0},{"id":"2618381946","title":"港股通创新药迎流动性+基本面共振 南方基金叶震南：回调后底部布局价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2618381946","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618381946?lang=zh_cn&edition=full","pubTime":"2026-03-11 18:28","pubTimestamp":1773224880,"startTime":"0","endTime":"0","summary":"过去几个月港股创新药板块虽受情绪与资金结构扰动，但“出海兑现—前沿技术—商业化拐点”的主线未变，优质龙头的临床管线推进仍然迅速，中国药企的全球竞争力仍在不断提升，估值仍有很大的潜力空间，回调后更值得在底部关注。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-03-11/doc-inhqrmmk2478461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK4585","06978","VXUS","BK4588","159992","BK1161"],"gpt_icon":0},{"id":"2618485059","title":"京新药业：地达西尼作为公司的首个创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2618485059","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618485059?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:24","pubTimestamp":1773221060,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问地达西尼所谓授权正在进行中，是跟菲律宾医药公司在谈么？京新药业回复：您好！地达西尼作为公司的首个创新药，一方面，希望取得较好的销售业绩；另一方面，也希望可以在一些国家推进授权工作，为公司贡献利润。目前相关工作在积极推进中，敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","002020","BK1161","06978","BK0239","BK1574"],"gpt_icon":0},{"id":"2618940752","title":"“医药一哥”被放鸽子，又一个国产创新药BD交易遭“退货”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940752","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618940752?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:06","pubTimestamp":1773216373,"startTime":"0","endTime":"0","summary":"近年来，中国创新药BD交易市场火热。另有报告显示，2026年1—2月中国创新药BD交易总额达532.76亿美元，交易数量达44笔。近日，知名跨国药企默克宣布终止与“医药一哥”恒瑞医药围绕PARP1抑制剂HRS-1167的全球授权合作。而对于恒瑞医药方面，业内指出，这笔合作终止“有得有失”。恒瑞医药的遭遇并非孤例，BD交易可谓是“冰火两重天”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119104197ad9ac2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119104197ad9ac2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","BK1515","LU0359202008.SGD","LU1023057109.AUD","06978","LU0359201612.USD","LU0359201885.HKD","BK1574","BK1161","09939","01276","BK1191"],"gpt_icon":0},{"id":"2618915830","title":"中国银河证券：医保省级统筹或成医药中长期投资新起点 医疗服务、创新药等板块值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2618915830","media":"智通财经","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618915830?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:10","pubTimestamp":1773209440,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，医保基金省级统筹推进提速，提升医保资金使用效率，有望成为医药投资新起点。通过推进省级统筹与个人账户跨省共济，有望盘活医保存量结余资金，有效破解医保收支结构性矛盾，扭转支出增速放缓趋势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","06881","601881","BK0188","BK1515","BK1574","159938","BK1564","09939","BK0276","06978","BK1147","161027"],"gpt_icon":0},{"id":"2618925435","title":"医药生物行业周报：罗伐昔替尼达成高额独家授权协议，创新药BD交易持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618925435","media":"上海证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618925435?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:05","pubTimestamp":1773209138,"startTime":"0","endTime":"0","summary":"主要观点2026年3月4日，中国生物制药宣布与赛诺菲就罗伐昔替尼达成独家授权协议。根据协议，中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。四起交易均为临床前资产，彰显中国源头创新能力获全球认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0140636845.USD","IE00B031HY20.USD","LU0072913022.USD","BK1191","06978","01093","LU1152091754.HKD","LU1226287792.SGD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU0314109678.HKD","LU1960683339.HKD","LU1328277881.USD","LU0501845795.SGD","LU0880133367.SGD","IE0008369823.USD","LU1951186391.HKD","BK1515","LU2039709279.SGD","BK1521","HK0000165453.HKD","BK1574","LU1226288253.USD","LU1807302812.USD","IE0008368742.USD","LU1008478684.HKD","LU1813983027.USD","LU0067412154.USD","LU1152091168.USD","IE00BZ08YT58.USD","LU1226287875.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","SG9999004220.SGD","BK1161","LU1993786604.SGD","LU1226287529.USD","LU0315179316.USD","IE00B543WZ88.USD","01801","01177","LU1226288170.HKD"],"gpt_icon":0},{"id":"2618191812","title":"政策加码商业健康险：创新药支付破局进行时","url":"https://stock-news.laohu8.com/highlight/detail?id=2618191812","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618191812?lang=zh_cn&edition=full","pubTime":"2026-03-11 13:24","pubTimestamp":1773206640,"startTime":"0","endTime":"0","summary":"在我国多层次医疗保障体系加快完善的背景下，商业健康保险的制度定位与支撑作用进一步凸显。2026年政府工作报告中，“推出商业健康保险创新药目录”被列为过去一年的重要民生成绩，并明确提出今年要“加快发展商业健康保险，推动创新药和医疗器械高质量发展，更好满足人民群众多元化就医用药需求。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-03-11/doc-inhqqupv5694294.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-11/doc-inhqqupv5694294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","159992","BK1574"],"gpt_icon":0},{"id":"2618528995","title":"复星医药创新药万缇乐开出中国首张处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2618528995","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618528995?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:09","pubTimestamp":1773191345,"startTime":"0","endTime":"0","summary":"本报讯（记者金婉霞）3月10日，上海复星医药（集团）股份有限公司（以下简称“复星医药”）表示，由该公司许可引进的创新药盐酸替那帕诺片（商品名：万缇乐）的中国首张处方，由北京大学人民医院肾内科主任左力教授开出。作为全球首个且目前唯一获批的磷吸收抑制剂，盐酸替那帕诺片的商业上市标志着高磷血症治疗领域迎来颠覆性突破，为中国的慢性肾脏病（CKD）透析患者带来全新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113668288895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0196","BK1515","BK1593","BK0012","BK0060","BK0096","159992","02196","BK1161","BK0175","06978","600196","BK0188","BK0028","BK0239","BK1574","BK0187","BK1191"],"gpt_icon":0},{"id":"2618196721","title":"跨国药企2025年成绩单：“药王”易主，创新药资产交易创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618196721","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618196721?lang=zh_cn&edition=full","pubTime":"2026-03-11 07:00","pubTimestamp":1773183600,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。面向2026年，全球制药行业的增长分化态势或将进一步延续。2025年，礼来大单品替尔泊肽势头强劲，成功锁定全球“药王”称号。其2025年财报显示，司美格鲁肽作为“王牌单品”实现361亿美元销售额，同比增长超过10%。作为2025年中国区业绩增速第三的跨国药企，诺华凭借创新药上市与本地化布局实现稳步增长。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-03-11/doc-inhqqixz5727235.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-11/doc-inhqqixz5727235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","BK1161","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.1059},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.0777},{"period":"6month","weight":-0.4528},{"period":"1year","weight":-0.4276},{"period":"ytd","weight":-0.1092}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0237},{"period":"6month","weight":-0.0399},{"period":"1year","weight":0.0782},{"period":"ytd","weight":0.0079}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.085186},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}